Adc Therapeutics SA
Research Adc Therapeutics SA (ADCT) on Bullrun: market cap USD 131.01M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerADCT
- ExchangeNYSE
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 131.01M
- Financial periodFY2025
- RevenueUSD 81.36M
- Revenue growth14.9%
- Net income-USD 142.60M
- Free cash flow-USD 141.44M
- Gross margin92.9%
Valuation Snapshot
latest market cap is USD 131.01M.
About Adc Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Frequently asked questions
What is Adc Therapeutics SA's market cap?
Adc Therapeutics SA's market capitalization is USD 131.01M.
What does Adc Therapeutics SA do?
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.